Loading...
XTAE
PSTI
Market cap45mUSD
, Last price  
ILS
Name

Pluri Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
27.72%
Rev. gr., 5y
43.27%
Revenues
326k
+13.59%
000000-1,682,000716,000679,000379,000379,0002,847,000050,00054,00023,0000234,000287,000326,000
Net income
-21m
L-26.25%
-2,098,108-2,439,724-8,428,900-10,498,000-6,636,000-7,453,000-10,848,000-14,794,000-21,155,000-26,932,000-24,677,000-23,246,000-27,814,000-26,126,000-35,213,000-29,348,000-49,943,000-41,023,000-28,321,000-20,888,000
CFO
-18m
L-21.16%
-1,791,836-2,047,193-3,071,391-4,537,000-4,262,000-5,408,000-5,755,000-3,275,000-16,887,000-19,121,000-20,605,000-18,522,000-21,611,000-21,380,000-29,453,000-26,369,000-30,910,000-36,501,000-22,857,000-18,021,000
Earnings
Sep 16, 2025

Profile

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation; and a solution for the treatment of acute radiation syndrome through its collaboration in the United States with the National Institutes of Health and the U.S. Department of Defense. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
IPO date
Dec 10, 2007
Employees
154
Domiciled in
IL
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
326
13.59%
287
22.65%
Cost of revenue
22,484
27,533
Unusual Expense (Income)
NOPBT
(22,158)
(27,246)
NOPBT Margin
Operating Taxes
277
Tax Rate
NOPAT
(22,158)
(27,523)
Net income
(20,888)
-26.25%
(28,321)
-30.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
91
8,024
BB yield
-0.30%
-218.38%
Debt
Debt current
1,118
627
Long-term debt
34,638
35,653
Deferred revenue
Other long-term liabilities
605
598
Net debt
5,771
(4,518)
Cash flow
Cash from operating activities
(18,021)
(22,857)
CAPEX
(323)
(262)
Cash from investing activities
10,584
9,698
Cash from financing activities
8,841
8,024
FCF
(21,083)
(26,835)
Balance
Cash
29,985
40,171
Long term investments
627
Excess cash
29,969
40,784
Stockholders' equity
(415,153)
(397,639)
Invested Capital
451,344
443,442
ROIC
ROCE
EV
Common stock shares outstanding
5,240
4,582
Price
5.78
620.70%
0.80
-34.80%
Market cap
30,289
724.32%
3,674
-25.76%
EV
41,379
1,101
EBITDA
(21,905)
(26,884)
EV/EBITDA
Interest
866
843
Interest/NOPBT